654-P: Greater Adherence and Persistence with Dulaglutide Compared with Semaglutide at 6- and 12-Months Follow-up in U.S. Real-World Data

The objective of this retrospective, observational study was to compare 6- and 12-month (mo) adherence and persistence among dulaglutide (DU) vs. matched semaglutide (SEMA) initiators using real-world administrative claims data from the IBM MarketScan Databases. Adult patients (pts) with T2D newly initiating DU or SEMA between January 2018-January 2020 (index date=earliest fill date), without evidence of GLP-1 RA use, pregnancy, gestational diabetes, or bariatric surgery in the 6-mo baseline period, and with continuous enrollment in the 6-mo baseline and 6- or 12-mo follow-up periods were included. DU initiators were propensity-score matched 1:1 to SEMA initiators for each 6- and 12-mo follow-up (26,284 and 13,837 pairs, respectively). Baseline characteristics were balanced with mean age 53 years and 50% females. More DU pts were adherent than SEMA pts (6mo:63% vs. 48%, 12mo: 54% vs. 43%, p values Disclosure R. Mody: Employee; Self; Eli Lilly and Company. J. Manjelievskaia: Employee; Self; IBM Watson Health, Research Support; Self; Eli Lilly and Company. M. Yu: Employee; Self; Lilly Diabetes, Employee; Spouse/Partner; LifeLabs, Stock/Shareholder; Self; Lilly Diabetes, Stock/Shareholder; Spouse/Partner; Lilly Diabetes. E. H. Marchlewicz: Research Support; Self; Eli Lilly and Company. R. Malik: Employee; Self; Eli Lilly and Company. N. Zimmerman: Consultant; Self; Eli Lilly and Company, Employee; Self; IBM Watson Health. D. E. Irwin: Employee; Self; IBM Watson Health.